Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary T Ferguson

Showing results (71-80 of 103) with videos related to

Pageof 11
Sort By:
Advances in Therapy|July 4, 2019
A Randomized, Double-Blind, Double-Dummy Study of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Relative to Umeclidinium/Vilanterol Dry Powder Inhaler in COPDFrançois Maltais, Gary T Ferguson, Gregory J Feldman, et al.
COPD|February 19, 2015
One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2-4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled AnalysisLorcan McGarvey, Dennis Niewoehner, Sheldon Magder, et al.
International Journal of Chronic Obstructive Pulmonary Disease|April 22, 2021
Peak Inspiratory Flow Rate in COPD: An Analysis of Clinical Trial and Real-World DataMartin Anderson, Kathryn Collison, M Bradley Drummond, et al.
The Lancet. Respiratory Medicine|November 13, 2018
Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trialWilliam W Busse, Eugene R Bleecker, J Mark FitzGerald, et al.
The Journal of Allergy and Clinical Immunology|February 20, 2021
Benralizumab for adolescent patients with severe, eosinophilic asthma: Safety and efficacy after 3 years of treatmentWilliam W Busse, Eugene R Bleecker, J Mark FitzGerald, et al.
Respiratory Research|June 2, 2011
Health status in the TORCH study of COPD: treatment efficacy and other determinants of changePaul W Jones, Julie A Anderson, Peter Ma Calverley, et al.
The Lancet. Respiratory Medicine|May 27, 2017
Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trialGary T Ferguson, J Mark FitzGerald, Eugene R Bleecker, et al.
Chest|July 8, 2009
Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health studyGary T Ferguson, Peter M A Calverley, Julie A Anderson, et al.
Respiratory Research|May 27, 2020
Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studiesFernando J Martinez, Brian J Lipworth, Klaus F Rabe, et al.
Respiratory Research|July 2, 2009
Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH studyChristine R Jenkins, Paul W Jones, Peter M A Calverley, et al.
Pageof 11

Showing results (71-80 of 103) with videos related to

Sort By:
Pageof 11
Advances in Therapy|July 4, 2019
A Randomized, Double-Blind, Double-Dummy Study of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Relative to Umeclidinium/Vilanterol Dry Powder Inhaler in COPDFrançois Maltais, Gary T Ferguson, Gregory J Feldman, et al.
COPD|February 19, 2015
One-Year Safety of Olodaterol Once Daily via Respimat® in Patients with GOLD 2-4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled AnalysisLorcan McGarvey, Dennis Niewoehner, Sheldon Magder, et al.
International Journal of Chronic Obstructive Pulmonary Disease|April 22, 2021
Peak Inspiratory Flow Rate in COPD: An Analysis of Clinical Trial and Real-World DataMartin Anderson, Kathryn Collison, M Bradley Drummond, et al.
The Lancet. Respiratory Medicine|November 13, 2018
Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trialWilliam W Busse, Eugene R Bleecker, J Mark FitzGerald, et al.
The Journal of Allergy and Clinical Immunology|February 20, 2021
Benralizumab for adolescent patients with severe, eosinophilic asthma: Safety and efficacy after 3 years of treatmentWilliam W Busse, Eugene R Bleecker, J Mark FitzGerald, et al.
Respiratory Research|June 2, 2011
Health status in the TORCH study of COPD: treatment efficacy and other determinants of changePaul W Jones, Julie A Anderson, Peter Ma Calverley, et al.
The Lancet. Respiratory Medicine|May 27, 2017
Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trialGary T Ferguson, J Mark FitzGerald, Eugene R Bleecker, et al.
Chest|July 8, 2009
Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health studyGary T Ferguson, Peter M A Calverley, Julie A Anderson, et al.
Respiratory Research|May 27, 2020
Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studiesFernando J Martinez, Brian J Lipworth, Klaus F Rabe, et al.
Respiratory Research|July 2, 2009
Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH studyChristine R Jenkins, Paul W Jones, Peter M A Calverley, et al.
Pageof 11